Table 4.
Response per mRECIST by independent review analysis
| Japan |
Overall |
|||
|---|---|---|---|---|
| lenvatinib (n = 81) | sorafenib (n = 87) | lenvatinib (n = 478) | sorafenib (n = 476) | |
| Complete response | 2.5 | 1.1 | 2.1 | 0.8 |
| Partial response | 44.4 | 11.5 | 38.5 | 11.6 |
| Stable disease | 32.1 | 47.1 | 33.3 | 46.0 |
| Durable stable disease | 16.0 | 20.7 | 17.6 | 18.9 |
| Progressive disease | 16.0 | 26.4 | 16.5 | 31.9 |
| Not evaluable/unknown | 4.9 | 13.8 | 9.6 | 9.7 |
| Overall response rate | 46.9 | 12.6 | 40.6 | 12.4 |
| 95% CI | 36.0–57.8 | 5.7–19.6 | 36.2–45.0 | 9.4–15.4 |
| p value* | <0.00001 | <0.00001 | ||
| Disease control rate | 79.0 | 59.8 | 73.8 | 58.4 |
| 95% CI | 70.1–87.9 | 49.5–70.1 | 69.9–77.8 | 54.0–62.8 |
| p value* | 0.00556 | <0.00001 | ||
Values are % unless otherwise indicated.
*
nominal.